Valeant Pharmaceuticals International Inc on Thursday raised its 2015 guidance for revenue and adjusted profit more than expected, as the drugmaker sees growth from existing products and a stream of acquisitions.The deal-making Laval, Quebec-based company failed in November to purchase Allergan Inc, when that company accepted a higher offer from Actavis PLC.Chief Executive Officer Michael Pearson said the company was likely to focus in 2015 on buying smaller, private companies."I look at the list now of our over 100 active conversations (with potential targets), the vast, vast majority are private companies," he said. "That's been our history, that's where our pipeline is now."
Shares of ACT traded higher by 1.49% or $3.95/share to $269.18. In the past year, the shares have traded as low as $174.94 and as high as $272.75. On average, 2996650 shares of ACT exchange hands on a given day and today's volume is recorded at 65017.
Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. Shares of AGN traded higher by 0.62% or $1.33/share to $215.44. In the past year, the shares have traded as low as $110.62 and as high as $214.87. On average, 3032380 shares of AGN exchange hands on a given day and today's volume is recorded at 104440.
Valeant Pharmaceuticals International, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. Shares of VRX traded higher by 3.95% or $5.73/share to $150.85. In the past year, the shares have traded as low as $106.00 and as high as $153.10. On average, 2262340 shares of VRX exchange hands on a given day and today's volume is recorded at 75999.
Source
